Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Safety and efficacy of the ultra-rush immunotherapy with extracts of Dermatophagoides pteronyssinus in children

집먼지 진드기 항원을 이용한 초급속면역치료의 안전성과 효과

  • Hyun, Sei Eun (Department of Pediatrics, College of Medicine, Pochon CHA University) ;
  • Kim, Hyoung Yun (Department of Pediatrics, College of Medicine, Pochon CHA University) ;
  • Kwak, Ji Hee (Department of Pediatrics, College of Medicine, Pochon CHA University) ;
  • Shin, Youn Ho (Department of Pediatrics, College of Medicine, Pochon CHA University) ;
  • Seo, Ji Yeong (Department of Pediatrics, College of Medicine, Pochon CHA University) ;
  • Han, Man Yong (Department of Pediatrics, College of Medicine, Pochon CHA University)
  • 현세은 (포천중문의과대학교 소아과학교실) ;
  • 김형윤 (포천중문의과대학교 소아과학교실) ;
  • 곽지희 (포천중문의과대학교 소아과학교실) ;
  • 신윤호 (포천중문의과대학교 소아과학교실) ;
  • 서지영 (포천중문의과대학교 소아과학교실) ;
  • 한만용 (포천중문의과대학교 소아과학교실)
  • Received : 2008.01.15
  • Accepted : 2008.07.11
  • Published : 2008.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Immunotherapy is accepted as the only treatment of allergic disease that can modify the natural course of the disease and ameliorate symptoms. This study aimed to evaluate the safety and efficacy of ultra-rush therapy using Dermatophagoides extracts in children. Methods : Of children older than four years who had visited Bundang CHA Pediatric Allergy Clinic, those showing positive reactions only to Dermatophagoides in the skin prick test and to the nasal provocation test were included. In all, 11 and 12 patients respectively preferred conventional and ultra-rush immunotherapy. We elevated allergen concentrations diluted to 1,000:1 of the end strength by 2-3 times with 30-minute intervals and checked oxygen saturation, pulse rate, blood pressure, and systemic reactions every 15 minutes. Immunotherapy effectiveness was valued by changes in nasal provocation test scores before and after immunotherapy. Results : The average ages of patients in the conventional and ultra-rush immunotherapy groups were $8.3{\pm}2.3$ and $9.2{\pm}2.8years$, respectively. Systemic reactions were observed in six in the ultra-rush group (50%) without anaphylaxis and one (9%) in the conventional group. The average scores in the nasal provocation test before and after treatment in the conventional group were $8.2{\pm}1.5$ and $4.6{\pm}2.1$, respectively (P=0.043). In the ultra-rush immunotherapy group, the scores changed from $6.2{\pm}2.2$ to $3.7{\pm}2.5$ (P=0.017). Conclusion : Ultra-rush immunotherapy using Dermatophagoides in children is effective for treating allergic disease but can induce systemic effects rather than conventional immunotherapy.

목 적 : 면역치료는 흡입성 알레르겐에 의해 유발되는 천식이나 비결막염, 곤충자상 치료에 매우 효과적이다. 이중 집먼지진드기 항원에 감작된 환아를 1-2일 내에 유지용량에 도달하는 초급속면역치료(ultra-rush immunotherapy)에 대한 안전성과 효과를 알아보고자 본 연구를 계획하였다. 방 법 : 분당차병원 소아 알레르기 클리닉에서 알러지성 비염 또는 기관지 천식으로 진단받은 4세 이상의 소아 중, 피부반응 검사에서 Dermatophagoides 항원에만 양성 반응을 보이고 비강유발검사에서 양성소견을 보인 환자를 대상자로 선정하였다. 고식적면역치료는 11명, 초급속면역치료를 신청한 소아는 12명이었다. 초급속면역치료는 목표 농도의 100:1-1,000:1로 희석한 알레르겐을 30분 간격으로 2-3배 증량하며, 주사 후 15분마다 산소포화도와 심박수, 혈압 및 전신반응 유무를 관찰하였고, 이때 나타난 환아의 증상을 점수화하였다. 면역치료의 효과 판정은 초기치료 3개월이 경과한 후에 비강유발검사를 실시하여 점수 변화로써 확인하였다. 결 과 : 고식적면역치료와 초급속면역치료 받은 소아의 평균나이는 각각 $8.3{\pm}2.3$세, $9.2{\pm}2.8$세였다. 초급속면역치료를 받은 12명중 6명(50%)에게서 전신반응이 관찰되었으며, 아나필락시스와 같은 심각한 부작용은 발현되지 않았다. 고식적면역치료의 경우 11명중 1명(9%)에서만이 전신반응이 관찰되었다. 치료 전후의 비강유발검사 평균 점수는 고식적면역치료 군의 경우 치료 전 $8.2{\pm}1.5$점, 치료 후 $4.6{\pm}2.1$점이었으며(P=0.043). 초급속면역치료에서는 치료 전 $6.2{\pm}2.2$점, 치료 후 $3.7{\pm}2.5$점으로(P=0.017) 두 군 모두 치료 전후 비강유발 검사 결과가 호전된 것을 알 수 있었다. 결 론 : 소아에서 Dermatophagoides를 이용한 초급속면역치료는 3개월 후 비강유발검사상 호전된 것을 확인할 수 있었으나 전신반응이 고식적 면역치료보다 높아 소아를 대상으로 시행함에 있어 면밀한 주의가 요구된다.

Keywords

References

  1. Joint Task Force on Practice Parameters. Allergen immunotherapy: A practice parameter. american academy of allergy, asthma and immunology. american college of allergy, asthma and immunology. Ann Allergy Asthma Immunol 2003;90(1 Suppl):1S-40S
  2. Sturm G, Kranke B, Rudolph C, Aberer W. Rush hyrnenoptera venom immunotherapy: A safe and practical protocol for high-risk patients. J Allergy Clin Immunol 2002;110:928-33 https://doi.org/10.1067/mai.2002.129124
  3. Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol 2006;16:79-85
  4. Birnbaum J. Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210 min): A safety study and risk factors. Clin Exp Allergy 2003;33:58-64 https://doi.org/10.1046/j.1365-2222.2003.01564.x
  5. Scribner TA, Bernstein DI. Rapid venom immunotherapy update. Curr Opin Allergy Clin Immunol 2003;3:295-8 https://doi.org/10.1097/00130832-200308000-00010
  6. van der Brempt X, Ledent C, Mairesse M. Accelerated desensitization for hymenoptera venom allergy in 30 hours: Efficacy and safety in 150 cases. Rev Med Brux 1997;18:120-4
  7. Schiavino D, Nucera E, Pollastrini E, De Pasquale T, Buonomo A, Bartolozzi F, et al. Specific ultrarush desensitization in hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol 2004;92:409-13 https://doi.org/10.1016/S1081-1206(10)61775-9
  8. Birnbaum J. Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210 min): A safety and risk factors. Clin Exp Allergy 2003;33:58-64 https://doi.org/10.1046/j.1365-2222.2003.01564.x
  9. Hirokawa Y, Kondo T, Kobayashi I, Ohta Y. Rush immunotherapy with house dust extract in patients with mild extrinsic asthma. Tohoku J Exp Med 1996;178:371-80 https://doi.org/10.1620/tjem.178.371
  10. Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized dermatophagoides pteronyssinus extract. IV. systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990;85:473-9 https://doi.org/10.1016/0091-6749(90)90157-Y
  11. Akmanlar N, Altintas DU, Guneser KS, Yilmaz M, Bingol G. Comparison of conventional and rush immunotherapy with der PI in childhood respiratory allergy. Allergol Immunopathol (Madr) 2000;28:213-8
  12. Litvyakova LI, Baraniuk JN. Nasal provocation testing: A review. Ann Allergy Asthma Immunol 2001;86:355-64 https://doi.org/10.1016/S1081-1206(10)62478-7
  13. Sharkey P, Portnoy J. Rush immunotherapy: Experience with a one-day schedule. Ann Allergy Asthma Immunol 1996;76:175-80 https://doi.org/10.1016/S1081-1206(10)63419-9
  14. Casanovas M, Martin R, Jimenez C, Caballero R, Fernandez-Caldas E. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. Int Arch Allergy Immunol 2006;139:153-8 https://doi.org/10.1159/000090392
  15. Golden DB, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of hymenoptera venom immunotherapy. Ann Intern Med 1980;92:620-4 https://doi.org/10.7326/0003-4819-92-5-620
  16. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001;87(1 Suppl):47S-55S https://doi.org/10.1016/S1081-1206(10)62195-3
  17. Ibero M, Castillo MJ Significant improvement of specific bronchial hyperreactivity in asthmatic children after 4 months of treatment with a modified extract of dermatophagoides pteronyssinus. J Investig Allergol Clin Immunol 2006;16:194-202
  18. Tabar AI, Fernandez-Tavora L, Alonso R, Castillo R, Cistero-Bahima A, de la Torre-Morin F, et al. Olerance of a cluster schedule with a house dust mite extract quantified in mass units: Multicentre study. J Investig Allergol Clin Immunol 2004;14:193-7
  19. Nagata M, Yamamoto H, Tabe K, Kimura I, Houya I, Kuramitsu K, et al. Effect of rush immunotherapy in house-dust-mite (HDM)-sensitive adult bronchial asthma: Changes in in vivo and in vitro responses to HDM. Intern Med 1993;32:702-9 https://doi.org/10.2169/internalmedicine.32.702
  20. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003;4:CD001186
  21. Boquete M, Carballada F, Exposito F, Gonzalez A. Preventive immunotherapy. Allergol Immunopathol (Madr) 2000;28:89-93
  22. Kohno Y, Minoguchi K, Oda N, Yokoe T, Yamashita N, Sakane T, et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol 1998;102(6 Pt 1):927-34 https://doi.org/10.1016/S0091-6749(98)70330-6
  23. Le Roux P, Le Luyer B. Accelerated desensitization to dermatophagoides pteronyssinus mites in children with asthma. results of two years of immunotherapy. Allerg Immunol (Paris) 1991;23:135-42
  24. Paty E, de Blic J, Brunet D, Le Bourgeois M, Garcelon M, Paupe J, et al. Accelerated desensitization with dermatophagoides pteronyssinus in severe asthmatic children. evaluation after one year of immunotherapy. Arch Fr Pediatr 1990;47:173-9
  25. Tabar AI, Echechipia S, Garcia BE, Olaguibel ]M, Lizaso MT, Gomez B, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with dermatop-hagoides pteronyssinus. J Allergy Clin Immunol 2005;116:109-18 https://doi.org/10.1016/j.jaci.2005.05.005
  26. Nanda A, O'connor M, Anand M, Dreskin SC, Zhang L, Hines B, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004;114:1339-44 https://doi.org/10.1016/j.jaci.2004.08.049

Cited by

  1. Safety of ultrarush immunotherapy vol.5, pp.6, 2008, https://doi.org/10.4168/aard.2017.5.6.305
  2. Safety of ultrarush allergen subcutaneous immunotherapy in children with allergic disease vol.5, pp.6, 2008, https://doi.org/10.4168/aard.2017.5.6.336
  3. Research on pediatric allergic rhinitis in Korea vol.6, pp.suppl1, 2008, https://doi.org/10.4168/aard.2018.6.s1.s58